Canada markets open in 5 hours 9 minutes

RetinalGenix Technologies Inc. (RTGN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.50000.0000 (0.00%)
At close: 01:47PM EDT

RetinalGenix Technologies Inc.

1450 North Mcdowell Boulevard
Suite 150
Petaluma, CA 94954
United States
415 578 9583
https://retinalgenix.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 

Key Executives

NameTitlePayExercisedYear Born
Dr. Jerry KatzmanCEO, President & ChairmanN/AN/A1953
Mr. Virender K. AhluwaliaInterim Chief Financial OfficerN/AN/A1958
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX, a resolution retinal imaging diabetic screening system that provides a 200-degree field of view without requiring pupil dilation; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is based in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Corporate Governance

RetinalGenix Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.